Management Strategies for CLN2 Disease

Area of Science:

• Neuroscience
• Genetics
• Pediatrics

Background:

• CLN2 disease (neuronal ceroid lipofuscinosis type 2) is a rare, pediatric-onset, neurodegenerative lysosomal storage disorder.
• It results from tripeptidyl peptidase 1 (TPP1) enzyme deficiency, leading to severe symptoms like language delay, seizures, motor decline, and blindness.
• Current clinical practice relies on general childhood neurodisability experience due to a lack of specific evidence and management guidelines.

Purpose of the Study:

• To survey CLN2 disease experts regarding current management practices.
• To identify common goals and strategies in CLN2 disease management.
• To lay the groundwork for developing consensus-based management guidelines for CLN2 disease.

Main Methods:

• A survey was conducted among twenty-four CLN2 disease experts.
• A subset of these experts convened to discuss current management practices.
• The study analyzed expert opinions on disease management goals and strategies.

Main Results:

• Management goals and strategies for CLN2 disease are globally consistent among experts.
• Expert-guided management aligns with pediatric palliative care principles.
• Care focuses on maintaining function early on, shifting to quality of life as the disease progresses.

Conclusions:

• A multidisciplinary approach is essential for optimal CLN2 disease patient care.
• Expert consensus indicates consistent management principles.
• This study is a foundational step towards establishing evidence-based CLN2 disease management guidelines.